Michael J. Birrer
Impact in
- Reproductive Medicine top 0.02%
- Ovarian cancer diagnosis and treatment
- Oncology top 0.1%
- PARP inhibition in cancer therapy
- Cancer-related Molecular Pathways
Papers in
-
- RNA modifications and cancer 21
- Ubiquitin and proteasome pathways 19
-
- Ovarian cancer diagnosis and treatment 139
- Co-authors
- Samuel C. Mok (38 shared papers)Kathleen N. Moore (45 shared papers)Gini F. Fleming (22 shared papers)Bradley J. Monk (19 shared papers)John D. Minna (15 shared papers)Robert S. Mannel (19 shared papers)Mark F. Brady (14 shared papers)Anil K. Sood (11 shared papers)
- Journals
- Gynecologic Oncology (72 papers)Journal of Clinical Oncology (59 papers)Cancer Research (23 papers)Annals of Oncology (15 papers)Molecular and Cellular Biology (15 papers)
- Partner nations
- United StatesCanadaUnited Kingdom
In The Last Decade
Michael J. Birrer
423 papers receiving 25.3k citations
Michael J. Birrer's Hit Papers
Peers
Comparison fields: 5 of 160
- Reproductive Medicine 5.5k
- Oncology 8.2k
- Cancer Research 4.1k
- Obstetrics and Gynecology 1.3k
- Molecular Biology 12.1k
Countries citing papers authored by Michael J. Birrer
This map shows the geographic impact of Michael J. Birrer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael J. Birrer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael J. Birrer more than expected).
Fields of papers citing papers by Michael J. Birrer
This network shows the impact of papers produced by Michael J. Birrer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael J. Birrer. The network helps show where Michael J. Birrer may publish in the future.
Co-authors
The 25 scholars most cited alongside Michael J. Birrer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 433 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer Hit paper breakdown → | 2011 | 1668 |
| 2 | Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis Hit paper breakdown → | 1996 | 1612 |
| 3 | p53: A Frequent Target for Genetic Abnormalities in Lung Cancer Hit paper breakdown → | 1989 | 1054 |
| 4 | BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group Hit paper breakdown → | 2012 | 868 |
| 5 | Oncogenic and transcriptional cooperation with Ha-Ras requires phosphorylation of c-Jun on serines 63 and 73 Hit paper breakdown → | 1991 | 715 |
| 6 | Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study Hit paper breakdown → | 2014 | 449 |
| 7 | Antibody-Drug Conjugate-Based Therapeutics: State of the Science Hit paper breakdown → | 2019 | 339 |
| 8 | 1994 | 335 | |
| 9 | 2008 | 327 | |
| 10 | 2008 | 325 | |
| 11 | 2013 | 315 | |
| 12 | 2017 | 308 | |
| 13 | 2012 | 281 | |
| 14 | 2005 | 280 | |
| 15 | Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer Hit paper breakdown → | 2016 | 253 |
| 16 | 2000 | 246 | |
| 17 | 2005 | 238 | |
| 18 | 2008 | 216 | |
| 19 | 1997 | 207 | |
| 20 | 2009 | 205 |
About Michael J. Birrer
Michael J. Birrer is a scholar working on Molecular Biology, Reproductive Medicine, Oncology, Cancer Research and Pulmonary and Respiratory Medicine, having authored 433 papers that have together received 25.7k indexed citations. Recurring topics across this work include Ovarian cancer diagnosis and treatment (139 papers), PARP inhibition in cancer therapy (34 papers), Cancer-related Molecular Pathways (30 papers), RNA modifications and cancer (21 papers), Ubiquitin and proteasome pathways (19 papers), HER2/EGFR in Cancer Research (19 papers), Endometrial and Cervical Cancer Treatments (19 papers) and Advanced Breast Cancer Therapies (18 papers). The work is most often cited by research in Reproductive Medicine (5.5k citations), Oncology (8.2k citations), Cancer Research (4.1k citations), Obstetrics and Gynecology (1.3k citations) and Molecular Biology (12.1k citations). Michael J. Birrer has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Samuel C. Mok, Kathleen N. Moore, Gini F. Fleming, Bradley J. Monk, John D. Minna, Robert S. Mannel, Mark F. Brady, Anil K. Sood, Éva Szabó and Robert A. Burger. Their work appears in journals such as Gynecologic Oncology, Journal of Clinical Oncology, Cancer Research, Annals of Oncology and Molecular and Cellular Biology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.